SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
Safety of targeted therapies (TTs), chemotherapy (CT) or immune checkpoint inhibitors (ICIs) therapy is still unknown. Mortality of SARS-CoV-2-positive patients was statistically significantly higher. Serious adverse events (SAEs) were more frequent in those treated with ICIs and CT.

Related Post